Gilead tries again with twice-yearly HIV drug lenacapavir

Gilead tries again with twice-yearly HIV drug lenacapavir

Source: 
Pharmaforum
snippet: 

Gilead Sciences has refiled for FDA approval of its HIV capsid inhibitor lenacapavir – which only needs to be dosed every six months – after the drug was rejected by the regulator in February.